Tamilvanan Shunmugaperumal - Oil-in-Water Nanosized Emulsions for Drug Delivery and Targeting

31 Goldstein, D., Nassar, T., Lambert, G. et al. (2005), The design and evaluation of a novel targeted drug delivery system using cationic emulsion‐antibody conjugates, J. Control. Release, 108, 418–432. doi:10.1016/j.jconrel.2005.08.021

32 Goldstein, D., Sader, O., and Benita, S. (2007b), Influence of oil droplet surface charge on the performance of antibody‐emulsion conjugates, Biomed. Pharmacother., 61, 97–103. doi:10.1016/j.biopha.2006.08.005

33 Grigoriev, D.O. and Miller, R. (2009), Mono‐ and multilayer covered drops as carriers, Curr. Opin. Colloid Interface Sci., 14, 48–59. doi:10.1016/j.cocis.2008.03.003

34 Hagigit, T., Abdulrazik, M., Orucov, F. et al. (2010), Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye, J. Control. Release, 145 (3), 297–305. doi:10.1016/j.jconrel.2010.04.013

35 Hagigit, T., Nassar, T., Behar‐Cohen, F. et al. (2008), The influence of cationic lipid type on in vitro release kinetics of antisense oligonucleotide from cationic nanoemulsions, Eur. J. Pharm. Biopharm., 70 (1), 248–259. doi:10.1016/j.ejpb.2008.03.005

36 Han, J. and Washington, C. (2005), Partition of antimicrobial additives in an intravenous emulsion and their effect on emulsion physical stability, Int. J. Pharm., 288 (2), 263–271. doi:10.1016/j.ijpharm.2004.10.002

37 Hu, Z., Deng, Y., and Sun, Q. (2004), Synthesis of precipitated calcium carbonate nanoparticles using a two‐membrane system, Colloid J., 66 (6), 745–750. doi:10.1007/s10595‐005‐0017‐4

38 ICH (2005), Q9 quality risk management, (Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf.) Accessed on August 1, 2019.

39 ICH (2008), Q10 pharmaceutical quality system, (Availabe at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf.) Accessed on August 1, 2019.

40 ICH (2009), Q8(R2) pharmaceutical development. Part I: pharmaceutical development, and Part II: annex to pharmaceutical development, (Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf.) Accessed on August 1, 2019.

41 Ishii, F. and Nii, T. (2005), Properties of various phospholipid mixtures as emulsifiers or dispersing agents in nanoparticle drug carrier preparation, Colloids Surf. B Biointerfaces, 41 (4), 257–262. doi:10.1016/j.colsurfb.2004.12.018

42 Joglekar, A.T. (1987), Product excellence through design of experiments, Cereal Foods World, 32, 857–868.

43 Jumaa, M., Furkert, F.H., and Müller, B.W. (2002), A new lipid emulsion formulation with high antimicrobial efficacy using chitosan, Eur. J. Pharm. Biopharm., 53 (1), 115–123. doi:10.1016/s0939‐6411(01)00191‐6

44 Jumaa, M. and Müller, B.W. (1998), The effect of oil components and homogenization condition on the physicochemical properties and stability of parenteral fat emulsions, Int. J. Pharm., 163 (s1–s2), 81–89. doi:10.1016/S0378‐5173(97)00369‐4

45 Jumaa, M. and Müller, B.W. (1999), Physicochemical properties of chitosan‐lipid emulsions and their stability during the autoclaving process, Int. J. Pharm., 183 (2), 175–184. doi:10.1016/s0378‐5173(99)00086‐1

46 Jumaa, M. and Müller, B.W. (2002), Parenteral emulsions stabilized with a mixture of phospholipids and PEG‐660‐12‐hydroxy‐stearate: evaluation of accelerated and long‐term stability, Eur. J. Pharm. Biopharm., 54 (2), 207–212. doi:10.1016/s0939‐6411(02)00057‐7

47 Kador, P.F. and Kinoshita, J.H. (1978), Phospholipid effects on the rat lens transport systems, Exp. Eye Res., 26 (6), 657–665. doi:10.1016/0014‐4835(78)90100‐8

48 Kim, T.W., Chung, H., Kwon, I.C. et al. (2005), Airway gene transfer using cationic emulsion as a mucosal gene carrier, J. Gen. Med., 7 (6), 749–758. doi:10.1002/jgm.711

49 Kim, Y.J., Kim, T.W., Chung, H. et al. (2003), The effects of serum on the stability and the transfection activity of the cationic lipid emulsion with various oils, Int. J. Pharm., 252 (1–2), 241–252. doi:10.1016/s0378‐5173(02)00676‐2

50 Lan, Q., Yang, F., Zhang, S. et al. (2007), Synergistic effect of silica nanoparticle and cetyltrimethyl ammonium bromide on the stabilization of O/W emulsions, Colloids Surf. A Physicochem. Eng. Aspects, 302 (1–3), 126–135. doi:10.1016/j.colsurfa.2007.02.010

51 Lance, M.R., Washington, C., and Davis, S.S. (1995), Structure and toxicity of amphotericin B/triglyceride emulsion formulations, J. Antimicrob. Chemother., 36 (1), 119–128. doi:10.1093/jac/36.1.119

52 Landfester, K. (2006), Synthesis of colloidal particles in miniemulsions, Annu. Rev. Mater. Res., 36, 231–279. doi:10.1146/annurev.matsci.36.032905.091025

53 Lee, V.H.L. and Robinson, J.R. (1986), Review: topical ocular drug delivery: recent developments and future challenges, J. Ocul. Pharmacol., 2 (1), 67–108. doi:10.1089/jop.1986.2.67

54 Liang, H., Brignole‐Baudouin, F., Rabinovich‐Guilatt, L. et al. (2008), Reduction of quaternary ammonium‐induced ocular surface toxicity by emulsions: an in vivo study in rabbits, Mol. Vis., 14, 204–216. http://www.molvis.org/molvis/v14/a26

55 Liu, Y., Mounkes, L.C., Liggitt, H.D. et al. (1997), Factors influencing the efficiency of cationic liposome‐mediated intravenous gene delivery, Nat. Biotechnol., 15 (2), 167–173. doi:10.1038/nbt0297‐167

56 Lundberg, B.B., Griffiths, G., and Hansen, H.J. (1999), Conjugation of an anti‐B‐cell lymphoma monoclonal antibody, LL2, to long‐circulating drug‐carrier lipid emulsions, J. Pharm. Pharmacol., 51, 1099–1105. doi:10.1211/0022357991776787

57 Lundberg, B.B., Griffiths, G., and Hansen, H.J. (2004), Cellular association and cytotoxicity of anti‐CD74‐targeted lipid drug‐carriers in B lymphoma cells, J. Control. Release, 94 (1), 155–161. doi:10.1016/j.jconrel.2003.09.016

58 Memisoglu, E., Bochot, A., Sen, M. et al. (2002), Amphiphilic β‐cyclodextrins modified on the primary face: synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules, J. Pharm. Sci., 91 (5), 1214–1224. doi:10.1002/jps.10105

59 Midmore, B.R. (1998), Synergy between silica and polyoxyethylene surfactants in the formation of o/w emulsions, Colloids Surf. A Physicochem. Eng. Aspects, 145 (1–3), 133–143. doi:10.1016/S0927‐7757(98)00577‐9

60 Montgomery, D.C. (2013), Design and Analysis of Experiments, 8th ed., Wiley, Hoboken, NJ; Chapter 1 (p. 3,19), Chapter 11 (p. 501), Chapter 14 (p. 605).

61 Moolman, F.S., Rolfes, H., van der Merwe, S.W. et al. (2004), Optimization of perfluorocarbon emulsion properties for enhancing oxygen mass transfer in a bio‐artificial liver support system, Biochem. Eng. J., 19 (3), 237–250. doi:10.1016/j.bej.2004.02.003

62 Motwani, S.K., Copra, S. Talegaonkar, S. et al. (2008), Chitosan‐sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization, J. Pharm. Biopharm., 68 (3), 513–525. doi:10.1016/j.ejpb.2007.09.009

63 Muchtar, S. and Benita, S. (1994), Emulsions as drug carriers for ophthalmic use, Colloid Surf. A Physicochem. Eng. Aspects, 91 (3), 181–190. doi:10.1016/0927‐7757(94)02882‐6

64 Müllar, R.H. (1990), Colloidal Carriers for Controlled Drug Delivery and Targeting: Modification, Characterization and In Vivo Distribution, Wiss Verl‐Ges, Stuttgart, Germany.

65 Müller, R.H. and Schmidt, S. (2002). SolEmuls technology for i.v. emulsions of poorly soluble drugs: amphotericin B, in: Fourth World Meeting on Pharamceutics, Biopharmaceutics and Pharmaceutical Technology, Florence, pp. 1451–1452.

66 Nakajima, M., Nabetani, H., Ichikawa, S. et al. (2003), Functional emulsions, US Patent 6538019.